European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 409-419 , May 2007

Predictors of axillary lymph node metastasis in breast cancer: A systematic review

  • N.R. Patani

      Affiliations

    • Department of Surgery, Royal Free and University College Medical School, The Medical School Building, 74 Huntley Street, University College London, London WC1E 6AU, UK
    • ,
  • M.V. Dwek

      Affiliations

    • School of Biosciences, University of Westminster, UK
    • ,
  • M. Douek

      Affiliations

    • Department of Surgery, Royal Free and University College Medical School, The Medical School Building, 74 Huntley Street, University College London, London WC1E 6AU, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 207 679 6461; fax: +44 207 679 6462.

,Accepted 6 September 2006.

References 

  1. Baum M, Chaplain MA, Anderson AR, Douek M, Vaidya JS. Does breast cancer exist in a state of chaos?. Eur J Cancer. 1999;35:886–891
  2. Fisher B. Seminars of Bernard Fisher 1960—nature of cancer as systemic disease?. Bull Soc Int Chir. 1972;31(6):604–609
  3. Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet. 1975;140:528–534
  4. Wolmark N, Fisher B. Surgery in the primary treatment of breast cancer. Breast Cancer Res Treat. 1981;1:339–348
  5. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–1232
  6. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241
  7. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med. 1997;337(14):949–955
  8. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg. 1996;131(3):301–308
  9. Fentiman IS. The dilemma of in situ carcinoma of the breast. Int J Clin Pract. 2001;55:680–683
  10. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?. Cancer. 1994;73(3):664–667
  11. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;19(352):930–942
  12. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:71–85
  13. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–553
  14. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398
  15. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–2350
  16. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(9069):1864–1867
  17. Veronesi U, Paganelli G, Viale G, et al. Sentinel Lymph Node Biopsy and Axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91(4):368–373
  18. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542–2551
  19. Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91(10):1245–1252
  20. Cox CE, Salud CJ, Harrinton MA. The role of selective sentinel lymph node dissection in breast cancer. Surg Clin North Am. 2000;80:1759–1777
  21. Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst. 1994;86:1771–1775
  22. Mansel RE, Goyal A, Fallowfield L, Newcombe RG. First results of the randomized multicenter ALMANAC trial. J Clin Oncol. 2004;22(14s):506
  23. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103(3):492–500
  24. Kocsis L, Svebis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg. 2004;70(11):1019–1024
  25. Callejo IP, Brito JA, Bivar JW, et al. Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node. Clin Transl Oncol. 2005;7(1):18–22
  26. Cserni G, Burzykowski T, Vinh-Hung V, et al. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol. 2004;34(9):519–524
  27. Fleming FJ, Kavanagh D, Crotty TB, et al. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57(1):73–76
  28. Hung WK, Chan MC, Mak KL, et al. Non-sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes. ANZ J Surg. 2005;75(1–2):27–31
  29. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241(1):152–158
  30. Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005;12(9):697–704
  31. Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use?. Breast. 2005;14:617–623
  32. Anan K, Mitsuyama S, Tamae K, et al. Axillary lymph node metastases in patients with small carcinomas of the breast: Is accurate prediction possible?. Eur J Surg. 2000;166(8):610–615
  33. Olivotto IA, Jackson JS, Mates D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer. 1998;83(5):948–955
  34. Ahlgren J, Stal O, Westman G, Arnesson LG. Prediction of axillary lymph node metastases in a screened breast cancer population. South-east Sweden Breast Cancer Group. Acta Oncol. 1994;33:603–608
  35. Santamaria G, Velasco M, Farre X, Vanrell JA, Cardesa A, Fernandez PL. Power doppler sonography of invasive breast carcinoma: Does tumor vascularization contribute to prediction of axillary status?. Radiology. 2005;234(2):374–380
  36. Mussurakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology. 1997;203:317–321
  37. Vaidya JS, Vyas JJ, Thakur MH, Khandelwal KC, Mittra I. Role of ultrasonography to detect axillary node involvement in operable breast cancer. Eur J Surg Oncol. 1996;22:140–143
  38. Yang WT, Ahuja A, Tang A, Suen M, King W, Metreweli C. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med. 1996;15(3):241–246
  39. Motomura K, Inaji H, Komoike Y, et al. Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol. 2001;27(2):141–145
  40. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg. 2006;93(6):707–712
  41. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–285
  42. Murray AD, Staff RT, Redpath TW, et al. Dynamic contrast enhanced MRI of the axilla in women with breast cancer: Comparison with pathology of excised nodes. Br J Radiol. 2002;75(891):220–228
  43. Stadnik TW, Everaert H, Makkat S, Sacre R, Lamote J, Bourgain C. Breast imaging. Preoperative breast cancer staging: Comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings. Eur Radiol. 2006 Oct;16(10):2153–2160
  44. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187
  45. de la HJ, Gomez A, Duenas R, et al. The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. Eur J Surg Oncol. 2004;30(3):346–351
  46. Chen M, Palleschi S, Khoynezhad A, Gecelter G, Marini CP, Simms HH. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg. 2002;137(5):606–609
  47. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C.W. Elston & I.O. Ellis. Histopathology 1991; 19; 403–410. Histopathology. 2002;41:151
  48. van Diest PJ, van der WE, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57:675–681
  49. Orucevic A, Reddy VB, Bloom KJ, et al. Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002;8(6):349–355
  50. Hasebe T, Sasaki S, Imoto S, Ochiai A. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol. 2000;156:1701–1710
  51. Chua B, Ung O, Taylor R, Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg. 2001;71:723–728
  52. Brenin DR, Manasseh DM, El Tamer M, et al. Factors correlating with lymph node metastases in patients with T1 breast cancer. Ann Surg Oncol. 2001;8(5):432–437
  53. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65–71
  54. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol. 2005;18(1):143–152
  55. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64:2941–2955
  56. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer. 1994;73:350–353
  57. Mattfeldt T, Kestler HA, Sinn HP. Prediction of the axillary lymph node status in mammary cancer on the basis of clinicopathological data and flow cytometry. Med Biol Eng Comput. 2004;42:733–739
  58. Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer. 2005;93(10):1168–1174
  59. Mitsuyama S, Anan K, Toyoshima S, et al. Histopathological predictors of axillary lymph node metastases in patients with breast cancer. Breast Cancer. 1999;6(3):237–241
  60. Velanovich V, Szymanski W. Lymph node metastasis in breast cancer: common prognostic markers lack predictive value. Ann Surg Oncol. 1998;5:613–619
  61. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984;2:1102–1109
  62. Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. AlphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer. 2004;100:2543–2548
  63. Schneider J, Pollan M, Ruibal A, et al. Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer. Tumour Biol. 1999;20(6):319–330
  64. Eskelinen M, Lipponen P, Collan Y. Immunohistochemical staining of human breast cancer with a new tumour marker MCA: relation to axillary lymph node involvement, metastasis, and survival. Anticancer Res. 1990;10:591–596
  65. Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93(2):101–110
  66. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55(6):429–434
  67. Bukholm IR, Bukholm G, Nesland JM. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. APMIS. 2002;110:214–220
  68. Brooks SA, Leathem AJ. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet. 1991;338:71–74
  69. Noguchi M, Thomas M, Kitagawa H, et al. DNA ploidy and helix pomatia lectin binding as predictors of regional lymph node metastases and prognostic factors in breast cancer. Breast Cancer Res Treat. 1993;26(1):67–75
  70. Hirata K, Tagawa Y, Kashima K, et al. Frequency of chromosome 7 gain in human breast cancer cells: Correlation with the number of metastatic lymph nodes and prognosis. Tohoku J Exp Med. 1998;184(2):85–97
  71. De Marchis L, Contegiacomo A, D'Amico C, et al. Microsatellite instability is correlated with lymph node-positive breast cancer. Clin Cancer Res. 1997;3(2):241–248
  72. Kataoka A, Sadanaga N, Mimori K, et al. Overexpression of HRad17 MRNA in human breast cancer: Correlation with lymph node metastasis. Clin Cancer Res. 2001;7(9):2815–2820
  73. Grey SR, Dlay SS, Leone BE, Cajone F, Sherbet GV. Prediction of nodal spread of breast cancer by using artificial neural network-based analyses of S100A4, nm23 and steroid receptor expression. Clin Exp Metastasis. 2003;20:507–514
  74. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan;415(6871):530–536
  75. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009
  76. Nishidate T, Katagiri T, Lin ML, et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: Identification of genes associated with progression and metastasis. Int J Oncol. 2004;25(4):797–819
  77. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001;98(20):11462–11467
  78. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230:692–696
  79. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001;25:767–772
  80. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997;79:1918–1922
  81. Harden SP, Neal AJ, Al Nasiri N, Ashley S, Querci della RG. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. Breast. 2001;10:155–159
  82. Tan LG, Tan YY, Heng D, Chan MY. Predictors of axillary lymph node metastases in women with early breast cancer in Singapore. Singapore Med J. 2005;46:693–697
  83. Noguchi M, Ohta N, Thomas M, et al. Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer. Surg Oncol. 1993;2(1):51–58

PII: S0748-7983(06)00326-X

doi: 10.1016/j.ejso.2006.09.003

European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 409-419 , May 2007

Article Tools

* Image Usage & Resolution